Efficacy and Safety of High-Energy Selective Laser Trabeculoplasty for Steroid-Induced Glaucoma in Patients with Quiescent Uveitis

<i>Purpose</i>: To assess the efficacy and safety of high-energy selective laser trabeculoplasty (SLT) for steroid-induced glaucoma in patients with quiescent uveitis. <i>Methods</i>: A retrospective study of steroid-induced glaucoma in quiescent uveitic patients who underwent SLT at our center from December 2014 to November 2017 and had been followed up for at least 1 year. Intraocular pressure (IOP) and IOP-lowering medications were recorded at baseline, and at 1 week, 1 month, 3 months, 6 months and 12 months after SLT. Treatment success was defined as IOP ≤18 mmHg and a ≥ 20% reduction in IOP without additional glaucoma surgery. <i>Results</i>: Twenty eyes from 19 patients were included. At the 12-month visit, mean IOP and mean number of IOP-lowering medications were significantly reduced as compared to baseline with an overall success rate of 65.0%. <i>Conclusions</i>: High-energy SLT appeared to be an effective and safe procedure for steroid-induced glaucoma with quiescent uveitis.

<i>研究目的</i>：评估高能量选择性激光小梁成形术（selective laser trabeculoplasty，SLT）用于合并静止性葡萄膜炎的糖皮质激素诱导性青光眼患者的疗效与安全性。<i>研究方法</i>：本研究为回顾性研究，纳入2014年12月至2017年11月于本中心接受SLT治疗的静止性葡萄膜炎合并糖皮质激素诱导性青光眼患者，所有受试者均完成至少1年的随访。于基线及SLT术后1周、1个月、3个月、6个月、12个月记录眼压（intraocular pressure，IOP）及降眼压药物使用情况。治疗成功定义为眼压≤18mmHg且眼压较基线降低≥20%，且未行额外青光眼手术。<i>研究结果</i>：本研究共纳入19例患者的20只患眼。术后12个月随访时，平均眼压及平均降眼压药物使用数量较基线均显著降低，总体治疗成功率为65.0%。<i>研究结论</i>：高能量SLT用于合并静止性葡萄膜炎的糖皮质激素诱导性青光眼患者，展现出良好的有效性与安全性。